- Home
- TLPH vs SRTS Comparison
TLPH vs SRTS Comparison
Compare TLPH & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- SRTS
- Stock Information
- Founded
- TLPH 2005
- SRTS 2010
- Country
- TLPH United States
- SRTS United States
- Employees
- TLPH N/A
- SRTS N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- TLPH Health Care
- SRTS Health Care
- Exchange
- TLPH Nasdaq
- SRTS Nasdaq
- Market Cap
- TLPH 64.7M
- SRTS 52.9M
- IPO Year
- TLPH 2011
- SRTS 2016
- Fundamental
- Price
- TLPH $1.34
- SRTS $4.06
- Analyst Decision
- TLPH Strong Buy
- SRTS Strong Buy
- Analyst Count
- TLPH 1
- SRTS 3
- Target Price
- TLPH $6.00
- SRTS $8.00
- AVG Volume (30 Days)
- TLPH 318.3K
- SRTS 164.5K
- Earning Date
- TLPH 11-12-2025
- SRTS 11-06-2025
- Dividend Yield
- TLPH N/A
- SRTS N/A
- EPS Growth
- TLPH N/A
- SRTS N/A
- EPS
- TLPH N/A
- SRTS N/A
- Revenue
- TLPH $28,000.00
- SRTS $35,609,000.00
- Revenue This Year
- TLPH N/A
- SRTS N/A
- Revenue Next Year
- TLPH $14,533.26
- SRTS $47.33
- P/E Ratio
- TLPH N/A
- SRTS N/A
- Revenue Growth
- TLPH N/A
- SRTS N/A
- 52 Week Low
- TLPH $0.38
- SRTS $3.03
- 52 Week High
- TLPH $1.45
- SRTS $9.33
- Technical
- Relative Strength Index (RSI)
- TLPH 57.82
- SRTS 56.38
- Support Level
- TLPH $1.01
- SRTS $4.11
- Resistance Level
- TLPH $1.35
- SRTS $4.69
- Average True Range (ATR)
- TLPH 0.11
- SRTS 0.39
- MACD
- TLPH -0.01
- SRTS 0.05
- Stochastic Oscillator
- TLPH 80.49
- SRTS 58.64
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.